Evusheld could offer higher protection against variants and help vulnerable people ward off virus
- Follow our Australia news live blog for the latest updates
- Five reasons NSW Covid case numbers have stayed low since reopening
- Vaccine rollout tracker; Cases and data tracker
- NSW Covid restrictions; Victoria restrictions
- Download the free Guardian app; get our morning email briefing
Australia’s drugs regulator, the Therapeutic Goods Administration (TGA), has granted “provisional determination” to pharmaceutical company AstraZeneca for a long-acting antibody cocktail which has shown promise in preventing Covid-19 in adults.
Provisional determination is an early step in the drugs approval process and means AstraZeneca can now submit further data to the TGA from human trials about how the treatment works and its safety. Once the TGA has scrutinised the data, and if it is satisfied with it, it may grant Evusheld “provisional approval” for use in Australia in limited circumstances. Further data must be collected and given to the TGA even if this occurs.
Sign up to receive an email with the top stories from Guardian Australia every morning
